Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cognition researchers Cogstate has licensed its technology to Japanese pharmaceutical company Eisai
  • The company will initially receive US$1 million in royalty fees
  • Cogstate’s share price is up 7.69 per cent today, currently sitting at $0.21 apiece

Cognition researchers Cogstate have licensed its technology to Japanese pharmaceutical company Eisai.

The exclusive agreement will see Eisai promote Cogstate’s technology to the Japanese market as a digital assessment tool for cognition.

Cogstate’s clinical trials will be excluded from the agreement, so the company can continue to self market them.

Eisai will pay US$1 million as an upfront royalty fee and cover any additional development costs to tailor the product for the Japanese market.

CEO at Cogstate Brad O’Connor said: “We are honoured to align with Eisai as they progress their plans to address the unmet needs of patients through innovation… as we continue to work together in the quest for a cure for Alzheimer’s disease.”

Initially, the agreement is set for 10 years, with performance reviews at year five and eight to maintain exclusivity.

Additionally, the company is looking to raise $2.86 million from shareholders, to assist in funding the scientific, operational and technical support of Cogstate’s technology in Japan.

Cogstate’s share price is up 7.69 per cent today, currently sitting at $0.21 apiece, as of AEST 3:42 pm.

CGS by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…